December 4, 2023 04:40 AM ESTUpdated 01:55 PM

Updated: Roche buys obesity and diabetes biotech Carmot Therapeutics in $2.7B merger deal

Ayisha Sharma

News Reporter

Kyle LaHucik

Senior Reporter

Roche is jumping back into the GLP-1 space with a definitive merger agreement to acquire Carmot Therapeutics for $2.7 billion upfront. The deal gives Roche …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: Roche buys obesity and diabetes biotech Carmot Therapeutics in $2.7B merger deal

Ayisha Sharma

News Reporter

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Compounded weight loss drugs have resulted in misdosing, hospitalizations, FDA warns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Up­dat­ed: Roche buys obe­si­ty and di­a­betes biotech Car­mot Ther­a­peu­tics in $2.7B merg­er deal

News Reporter

Senior Reporter

Sign up to read this article for free.

Updated: Roche buys obesity and diabetes biotech Carmot Therapeutics in $2.7B merger deal